Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 1998, p. 1503-1505, Vol. 42, No. 6
Department of Pathology, Hershey Medical
Center, Hershey, Pennsylvania 17033,1 and
Department of Pathology, Case Western Reserve University,
Cleveland, Ohio 441062
Received 24 November 1997/Returned for modification 3 March
1998/Accepted 25 March 1998
Trovafloxacin pneumococcal and staphylococcal postantibiotic
effects (PAEs) were 0.7 to 1.8 and 0.7 to 2.4 h, respectively. For
Escherichia coli and Pseudomonas aeruginosa,
PAEs were 2.4 to 4.4 h. Pneumococcal and staphylococcal
postantibiotic sub-MIC effects (PA-SMEs) (0.4 times the MIC) were 2.3 to 3.7 and 2.4 to >9.2 h, respectively, and E. coli
PA-SMEs (0.3 times the MIC) were 6.8 to >12.0 h. For one P. aeruginosa strain, the PA-SME (0.4 times the MIC) was >10 h; in
the other, rapid bactericidal activity precluded measurement.
The postantibiotic effect (PAE) is a
pharmacodynamic parameter contributing to antibiotic dosing schedules.
It is defined as the length of time that bacterial growth is suppressed
following brief exposure to an antibiotic (4, 7).
Odenholt-Tornqvist and coworkers (2, 11, 12) have suggested
that during intermittent dosage regimens, suprainhibitory antibiotic
levels are followed by subinhibitory levels that persist between doses
and have hypothesized that persistent sub-MICs could extend the PAE.
The effect of sub-MICs on growth during the PAE period has been defined
as the postantibiotic sub-MIC effect (PA-SME), representing the time
interval that includes the PAE plus the additional time during which
growth is suppressed by sub-MICs. In contrast to the PA-SME, the
sub-MIC effect (SME) measures the direct effect of sub-MICs on cultures
which have not been previously exposed to antibiotics (2, 11,
12).
We examined the PAE, PA-SME, and SME of trovafloxacin, a
fluoroquinolone with a wide spectrum of activity (5, 6, 10, 13,
14), against two penicillin-susceptible, two intermediately penicillin-susceptible and two penicillin-resistant pneumococcal strains; two methicillin-susceptible and two methicillin-resistant Staphylococcus aureus strains; two Escherichia
coli strains; and two Pseudomonas aeruginosa strains.
Organisms were identified by standard methods (8).
Standard broth microdilution MIC-determining methodology (9)
was used. The PAE was determined by the viable plate count method
(4) using Mueller-Hinton broth supplemented with 5% lysed
horse blood when testing pneumococci. The PAE was induced by exposure
to a drug concentration equivalent to 10 times the MIC for 1 h.
Tubes containing 5 ml of broth with antibiotic were inoculated with
approximately 5 × 106 CFU/ml. Growth controls with an
inoculum but not antibiotic were included with each experiment. Tubes
were placed in a shaking water bath at 35°C for 1 h. At the end
of the exposure period, cultures were diluted 1:1,000 to remove the
antibiotic. A control containing bacteria pre-exposed to the antibiotic
at a concentration of 0.01 times the MIC was also prepared.
Viability counts (16) were determined before exposure,
immediately after dilution (0 h), and then every 2 h until tube
turbidity reached a no. 1 McFarland standard. Inocula were prepared by
suspending growth from an overnight blood agar plate in broth. The
broth was incubated at 35°C for 2 to 4 h in a shaking water bath
until the turbidity matched a no. 1 McFarland standard and checked for viability by plate counts (16).
The PAE was defined (4) as PAE = T The PA-SME and SME (12) were measured in two separate
experiments. In cultures designated for PA-SME determination, the PAE
was induced as described above, after exposure to a drug concentration of 10 times the MIC. Following 1:1,000 dilution, cultures were divided
into five tubes. To four tubes, trovafloxacin was added to make final
subinhibitory concentrations of 0.1, 0.2, 0.3, and 0.4 times the MIC.
The fifth tube received no antibiotic. Viability counts were determined
before exposure, immediately after dilution, and then every 2 h
until the turbidity reached a no. 1 McFarland standard. The PAE was not
induced in cultures designated for SME determination.
The PA-SME was defined (12) as PA-SME = Tpa Pneumococcal trovafloxacin MICs were all 0.06 µg/ml. Staphylococcal
trovafloxacin MICs were 0.016 µg/ml for the methicillin-susceptible strains and 1.0 µg/ml for the methicillin-resistant strains. The E. coli trovafloxacin MICs were 0.03 µg/ml, and those for
P. aeruginosa were 0.25 µg/ml.
Results are presented in Table 1. The
antibiotic at 0.01 times the MIC had no activity. The mean PAE for the
six pneumococci was 1.3 h, ranging from 0.7 to 1.8 h.
Pneumococcal PA-SMEs were slightly longer than PAEs. At 0.4 times the
MIC, PA-SMEs were 2.3 to 3.7 h, with a mean of 3.2 h.
Pneumococcal PA-SMEs approximated the sum of the PAE and the SME,
indicating that sub-MICs alone accounted for the slightly longer
PA-SMEs.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Postantibiotic Effect of Trovafloxacin against
Gram-Positive and -Negative Organisms
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
C, where T is the time required for viability counts of
an antibiotic-exposed culture to increase by 1 log10 above
the counts immediately after dilution and C is the
corresponding time for the growth control.
C, where
Tpa is the time for cultures previously exposed
to an antibiotic and then reexposed to different sub-MICs to increase
by 1 log10 above the counts determined immediately after
dilution and C is the corresponding time for the unexposed
control. The SME (12) was defined as SME = Ts
C, where
Ts is the time for the cultures exposed only to
sub-MICs to increase 1 log10 above the counts determined
immediately after dilution and C is the corresponding time
for the unexposed control. For each experiment, viability counts
(log10 CFU per milliliter) were plotted against time and results were expressed as the mean of two separate assays ± the standard deviation.
TABLE 1.
PAE, SME, and PA-SME of trovafloxacin against
14 strainsa
Staphylococcal PAEs were 0.7 to 2.4 h, with a mean of 1.3 h. PA-SMEs were longer than PAEs. PA-SMEs at 0.4 times the MIC ranged from 2.4 to >9.2 h. At 0.4 times the MIC, the PA-SMEs of two staphylococci were >2 h longer than the PAE plus the SME. This indicates that, for these two strains, sub-MICs delayed regrowth.
For both E. coli strains and one P. aeruginosa strain, PAEs were 2.4 to 4.4 h, with a mean of 3.5 h. The PA-SMEs of both E. coli strains were longer than the PAE plus the SME. At 0.3 times the MIC, the PA-SME was >2 h longer than the PAE plus the SME. For one strain of P. aeruginosa, the PA-SME at 0.4 times the MIC was >2 h longer than the sum of the PAE and the SME, indicating that sub-MICs suppressed the regrowth of these strains when they were pre-exposed to trovafloxacin in the PAE phase. Rapid bactericidal activity against one P. aeruginosa strain precluded measurement of the PAE or the PA-SME.
Trovafloxacin MICs were similar to those described previously (5, 6, 10). Trovafloxacin, like other quinolones, exhibits rapid, concentration-dependent bactericidal activity (3, 16). Longer intervals between doses may be possible when an antibiotic has a long half-life as well as a prolonged PAE and PA-SME, because regrowth continues to be prevented when drug levels in serum and tissue fall below the MIC. In this study, PAEs against gram-negative strains were generally longer than those against gram-positive strains, indicating possible differences between the rates at which trovafloxacin killed these organisms.
Boswell et al. (1) reported trovafloxacin PAEs between 0.3 and 2.3 h for four P. aeruginosa strains. The former study also reported, as we have, that the PAE against some P. aeruginosa strains could not be determined because of rapid killing.
PA-SMEs exceeded the sum of the PAE and the SME for two staphylococcal, one P. aeruginosa, and two E. coli strains, indicating that for these strains, trovafloxacin at sub-MICs had a greater effect on pre-exposed than on unexposed cultures. Therefore, a longer PAE can be achieved by trovafloxacin at sub-MICs when they follow a suprainhibitory level.
In this study, pre-exposure at 10 times the MIC was below clinically achievable trovafloxacin levels (15) for all strains except the two methicillin-resistant S. aureus strains. For the other strains, the MICs were so low that concentrations in serum would exceed the MIC for the entire recommended 24-h dosing interval (15). Our results suggest that a longer dosing interval may be possible for the latter strains with a PAE and a PA-SME, because bacterial regrowth would be prevented when drug levels in serum fall below the MIC.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by a grant from Pfizer, Inc., New York, N.Y.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psghs.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Boswell, F. J.,
J. M. Andrews, and R. Wise.
1997.
Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa.
J. Antimicrob. Chemother.
39:811-814 |
| 2. | Cars, O., and I. Odenholt-Tornqvist. 1993. The postantibiotic subMIC effect in vitro and in vivo. J. Antimicrob. Chemother. 31:159-166. |
| 3. | Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):6-8. |
| 4. | Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md. |
| 5. | Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. J. Antimicrob. Chemother. 37:366-370. |
| 6. |
Fass, R. J.,
J. Barnishan,
M. C. Solomon, and L. W. Ayers.
1996.
In vitro activities of quinolones, -lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.
Antimicrob. Agents Chemother.
40:1412-1418[Abstract].
|
| 7. |
MacKenzie, F. M., and I. M. Gould.
1993.
The post-antibiotic effect.
J. Antimicrob. Chemother.
32:519-537 |
| 8. | Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1995. Manual of clinical microbiology. ASM Press, Washington, D.C. |
| 9. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS publication no. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 10. |
Neu, H. C., and N.-X. Chin.
1994.
In vitro activity of the new fluoroquinolone CP-99,219.
Antimicrob. Agents Chemother.
38:2615-2622 |
| 11. |
Odenholt-Tornqvist, I.
1993.
Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.
J. Antimicrob. Chemother.
31:881-892 |
| 12. |
Odenholt-Tornqvist, I.,
E. Löwdin, and O. Cars.
1992.
Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
Antimicrob. Agents Chemother.
36:1852-1858 |
| 13. |
Pankuch, G. A.,
M. R. Jacobs, and P. C. Appelbaum.
1995.
Activity of CP 99,219 compared to DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.
J. Antimicrob. Chemother.
35:230-232 |
| 14. |
Spangler, S. K.,
M. R. Jacobs, and P. C. Appelbaum.
1994.
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Antimicrob. Agents Chemother.
38:2471-2476 |
| 15. |
Teng, R.,
S. C. Harris,
D. E. Nix,
J. J. Schentag,
G. Foulds, and T. E. Liston.
1996.
Pharmacokinetics and safety of trovafloxacin (CP-99,19), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
J. Antimicrob. Chemother.
36:385-394 |
| 16. |
Visalli, M. A.,
M. R. Jacobs, and P. C. Appelbaum.
1996.
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefotaxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
J. Antimicrob. Chemother.
37:77-84 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»